• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

    22.59 -0.87 (-3.71%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,098,724
    Open 23.44
    Bid (Size) 21.09 (3,500)
    Ask (Size) 21.55 (300)
    Prev. Close 23.46
    Today's Range 22.03 - 23.73
    52wk Range 18.80 - 27.98
    Shares Outstanding 44,454,792
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pacira BioSciences Inc (NASDAQ:PCRX) Misses Q4 Earnings and Revenue Estimates, Shares Drop ↗
    Via Chartmill
    News headline image
    Pacira (PCRX) Q4 2025 Earnings Call Transcript ↗
    Pacira (PCRX) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings Intellectual Property

    Performance

    YTD
    -7.6%
    -7.6%
    1 Month
    +10.2%
    +10.2%
    3 Month
    -5.1%
    -5.1%
    6 Month
    -13.5%
    -13.5%
    1 Year
    -10.0%
    -10.0%

    More News

    Read More
    News headline image
    Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira to Report 2025 Financial Results on Thursday February 26, 2026
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Bridge City Capital Loads Up Onto Innovation Stock With Over 31,000 Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
    From Pacira BioSciences
    Via GlobeNewswire
    News headline image
    Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
    From Pacira BioSciences
    Via GlobeNewswire

    Frequently Asked Questions

    Is Pacira BioSciences, Inc. - Common Stock publicly traded?
    Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
    What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
    Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
    The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
    What is the current price of Pacira BioSciences, Inc. - Common Stock?
    The current price of Pacira BioSciences, Inc. - Common Stock is 22.59
    When was Pacira BioSciences, Inc. - Common Stock last traded?
    The last trade of Pacira BioSciences, Inc. - Common Stock was at 02/26/26 04:00 PM ET
    What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
    The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.00B
    How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
    Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.